Unknown
PHASE2
INTERVENTIONAL
NCT02787447
Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The investigators postulated that the exploitation of the pro-immunogenic effects of radiotherapy with thymosin might result in abscopal responses among patients with metastatic cancer. The research is designed to evaluate the efficacy and toxicity of patients treated with hypofractionated radiotherapy combined with thymosin alpha 1. An exploratory biomarker analysis in blood and tumor samples is also planned.
Interventions
Name:
TKI
Type:
DRUG
Description:
Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
Name:
Thoracic Hypofractionated Radiotherapy
Type:
RADIATION
Description:
40-45 Gy/5-15f
Name:
Thymosin Alpha 1
Type:
DRUG
Description:
Initiating thymosin alpha 1 therapy(1.6mg, qd, d1-d14;1.6mg, biw, d15-d90) at the second week of radiotherapy.
Primary Outcomes
Measure:
The proportion of patients with an abscopal response assessed at 1-6 months after the radiation therapy
TimeFrame:
1-6 months
Description:
To assess the proportion of patients with an abscopal response (defined as at least a 30% decrease in the longest diameter of the best responding abscopal lesion) at 1-6 months after the radiation therapy
Trial Information
NCT ID
NCT02787447
Status
Unknown
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
First People's Hospital of Hangzhou
Last Updated
December 15, 2025